Notice: This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends RTRX vs. VRNA, RYTM, MLTX, JANX, XENE, EWTX, FOLD, MRUS, ACAD, and MORShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Verona Pharma (VRNA), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Edgewise Therapeutics (EWTX), Amicus Therapeutics (FOLD), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), and MorphoSys (MOR). These companies are all part of the "medical" sector. Travere Therapeutics vs. Verona Pharma Rhythm Pharmaceuticals MoonLake Immunotherapeutics Janux Therapeutics Xenon Pharmaceuticals Edgewise Therapeutics Amicus Therapeutics Merus ACADIA Pharmaceuticals MorphoSys Travere Therapeutics (NASDAQ:RTRX) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability. Do insiders & institutionals have more ownership in RTRX or VRNA? 85.9% of Verona Pharma shares are owned by institutional investors. 4.6% of Travere Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Verona Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, RTRX or VRNA? Travere Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Does the MarketBeat Community prefer RTRX or VRNA? Travere Therapeutics received 97 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 80.55% of users gave Verona Pharma an outperform vote while only 73.17% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes42073.17% Underperform Votes15426.83% Verona PharmaOutperform Votes32380.55% Underperform Votes7819.45% Does the media refer more to RTRX or VRNA? In the previous week, Verona Pharma had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 3 mentions for Verona Pharma and 0 mentions for Travere Therapeutics. Verona Pharma's average media sentiment score of 0.77 beat Travere Therapeutics' score of 0.00 indicating that Verona Pharma is being referred to more favorably in the news media. Company Overall Sentiment Travere Therapeutics Neutral Verona Pharma Positive Do analysts prefer RTRX or VRNA? Verona Pharma has a consensus target price of $43.83, indicating a potential upside of 4.32%. Given Verona Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Verona Pharma is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, RTRX or VRNA? Verona Pharma has lower revenue, but higher earnings than Travere Therapeutics. Verona Pharma is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$175.34M5.00-$146.43M-$3.46-4.97Verona Pharma$5.62M601.01-$54.37M-$1.92-21.89 Is RTRX or VRNA more profitable? Verona Pharma has a net margin of 0.00% compared to Travere Therapeutics' net margin of -49.13%. Travere Therapeutics' return on equity of -36.38% beat Verona Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-49.13% -36.38% -14.90% Verona Pharma N/A -79.54%-43.49% SummaryVerona Pharma beats Travere Therapeutics on 12 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$877.07M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-8.1410.5990.1317.19Price / Sales5.00196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book3.345.094.784.78Net Income-$146.43M$151.83M$120.31M$225.60M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$17.18-1.3%N/A+106.0%$877.07M$175.34M-8.14221High Trading VolumeVRNAVerona Pharma0.8422 of 5 stars$42.79+3.3%$43.83+2.4%+156.7%$3.48B$460,000.00-22.2730Positive NewsRYTMRhythm Pharmaceuticals4.1104 of 5 stars$54.69-1.0%$63.70+16.5%+24.3%$3.36B$77.43M-12.76140Analyst ForecastNews CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.6156 of 5 stars$52.45+2.2%$79.88+52.3%-11.0%$3.35BN/A-40.842JANXJanux Therapeutics3.6707 of 5 stars$61.79+1.1%$89.90+45.5%+466.0%$3.24B$13.05M-52.2330Positive NewsXENEXenon Pharmaceuticals2.7929 of 5 stars$41.30+3.1%$56.90+37.8%-7.0%$3.15B$9.43M-14.20251Insider TradeEWTXEdgewise Therapeutics2.7186 of 5 stars$32.99+19.4%$42.33+28.3%+234.9%$3.12BN/A-22.8560Analyst ForecastAnalyst RevisionHigh Trading VolumeFOLDAmicus Therapeutics4.321 of 5 stars$9.83+5.0%$16.88+71.7%-25.5%$2.94B$493.67M-28.71480Analyst DowngradeMRUSMerus2.6066 of 5 stars$42.90+0.2%$85.64+99.6%+58.5%$2.94B$35.93M-10.8437ACADACADIA Pharmaceuticals3.7007 of 5 stars$17.22-0.2%$25.60+48.7%-42.9%$2.87B$726.44M22.13510MORMorphoSys0.1266 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730News Coverage Related Companies and Tools Related Companies Verona Pharma Alternatives Rhythm Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Janux Therapeutics Alternatives Xenon Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Amicus Therapeutics Alternatives Merus Alternatives ACADIA Pharmaceuticals Alternatives MorphoSys Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RTRX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
